Last reviewed · How we verify
Clindamycin and BPO 5% gel
Clindamycin kills acne-causing bacteria while benzoyl peroxide oxidizes and destroys bacterial cell membranes and reduces sebum production.
Clindamycin kills acne-causing bacteria while benzoyl peroxide oxidizes and destroys bacterial cell membranes and reduces sebum production. Used for Acne vulgaris.
At a glance
| Generic name | Clindamycin and BPO 5% gel |
|---|---|
| Also known as | Duac Topical Gel |
| Sponsor | Stiefel, a GSK Company |
| Drug class | Topical antibiotic combination with keratolytic agent |
| Target | Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Propionibacterium acnes. Benzoyl peroxide (BPO) is an oxidizing agent that generates reactive oxygen species to destroy bacterial cell walls and also helps reduce comedone formation by normalizing follicular keratinization. The combination provides synergistic antibacterial activity and reduces the risk of antibiotic resistance.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Dryness
- Erythema
- Peeling
- Contact dermatitis
Key clinical trials
- Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty (PHASE4)
- Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris (PHASE3)
- Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris (PHASE4)
- W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne (PHASE1)
- Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications (PHASE4)
- Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin and BPO 5% gel CI brief — competitive landscape report
- Clindamycin and BPO 5% gel updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI